Reviewer’s report

Title: Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study

Version: 0 Date: 26 Sep 2017

Reviewer: Howard Fillit

Reviewer's report:

This paper is of interest because of the unique nature of the population under study. The study also includes a focus on societal costs. However, it is not clear to me that the study includes the costs of pharmaceuticals. While Table 1 lists the percent users of acetylcholinesterases and memantine, the section on data collection does not indicate that the costs of these drugs are included in the analysis. I think this is important, since the incremental cost savings indicated in the study are modest, and on an annual basis are not significantly different than the cost of these medications. The authors also do not discuss that, while they demonstrate cost savings based on slowing rate of decline, they also do not mention in the discussion, for example, that most of the newer disease modifying drugs being tested or anticipated will cost far more than the cost savings predicted by the modeling studies presented here.

Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English  
Please indicate the quality of language in the manuscript:
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal